# US 2022/0088150 A1 · Octreotide Microsphere-Based Arterial Embolization for Treating Obesity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0088150 A1
- Document ID: US20220088150A1
- Status: Published application
- Kind: A1
- Application number: 17/277,342
- Filed: 2019-09-19
- Published: 2022-03-24
- Earliest claimed: 2018-09-20
- Applicants: Biovena Science, LLC
- Inventors: Fuad Nurili; Omer Aras
- Web page: https://patentgrep.com/patent/US20220088150A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 38/31: Somatostatins
- A61K 9/1647: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61L 24/046: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds (A61L24/043 takes precedence)}
- A61P 3/04: Anorexiants; Antiobesity agents
- A61L 2300/252: Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L 2300/43: Hormones, e.g. dexamethasone
- A61L 2430/36: for embolization or occlusion, e.g. vaso-occlusive compositions or devices
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention provides a method for causing weight loss in a subject comprising introducing biodegradable microspheres into one or more of the subject's gastric arteries, wherein the microspheres (i) have a d90 value from 40 μm to 500 μm; (ii) comprise polylactic acid (PLA) and/or polylactic co-glycolic acid (PLGA); (iii) carry a therapeutically effective amount of pharmaceutical octreotide; (iv) embolize gastric arterial vessels supplied by the one or more arteries into which they are introduced; and (v) release octreotide during embolization.

## Claims

### Claim 1

A method for causing weight loss in a subject comprising introducing biodegradable microspheres into one or more of the subject's gastric arteries, wherein the microspheres (i) have a d90 value from 40 μm to 500 μm; (ii) comprise polylactic acid (PLA) and/or polylactic co-glycolic acid (PLGA); (iii) carry a therapeutically effective amount of pharmaceutical octreotide; (iv) embolize gastric arterial vessels supplied by the one or more arteries into which they are introduced; and (v) release octreotide during embolization.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is human.

### Claim 3 (depends on 2)

The method of claim 2, wherein the method comprises introducing the biodegradable microspheres into the subject's left gastric artery.

### Claim 4 (depends on 2)

The method of claim 2, wherein the subject has a body mass index (BMI) of 40 or higher.

### Claim 5 (depends on 2)

The method of claim 2, wherein each microsphere comprises PLA and PLGA.

### Claim 6 (depends on 5)

The method of claim 5, wherein each microsphere comprises PLA and PLGA at a PLA:PLGA molar ratio from 40:60 to 50:50.

### Claim 7 (depends on 6)

The method of claim 6, wherein each microsphere comprises PLA and PLGA at a PLA:PLGA molar ratio of 45:55.

### Claim 8 (depends on 2)

The method of claim 2, wherein the biodegradable microspheres have a d90 value from 50 μm to 200 μm.

### Claim 9 (depends on 8)

The method of claim 8, wherein the biodegradable microspheres have a d90 value from 70 μm to 150 μm.

### Claim 10 (depends on 2)

The method of claim 2, wherein the therapeutically effective amount of pharmaceutical octreotide is from 5 mg to 50 mg.

### Claim 11 (depends on 10)

The method of claim 10, wherein the therapeutically effective amount of pharmaceutical octreotide is from 10 mg to 20 mg.

### Claim 12 (depends on 10)

The method of claim 10, wherein the therapeutically effective amount of pharmaceutical octreotide is from 20 mg to 30 mg.

### Claim 13 (depends on 2)

The method of claim 2, wherein the embolization lasts from four to eight weeks.

### Claim 14

A method for causing weight loss in a human subject having a BMI of 40 or higher comprising introducing biodegradable microspheres into the subject's left gastric artery, wherein the microspheres (i) have a d90 value from 70 μm to 150 μm; (ii) comprise PLA and PLGA at a PLA:PLGA molar ratio of 45:55; (iii) carry from 10 mg to 20 mg of pharmaceutical octreotide; (iv) embolize gastric arterial vessels supplied by the left gastric artery; and (v) release octreotide during embolization.
